Xilio Therapeutics, Inc. (XLO)
Xilio Therapeutics, Inc. (XLO) Insider Trading
Directors, officers and holders of more than 10% of XLO report their trades in its stock on SEC Form 4, within two business days. Each row below is one Form 4 transaction line. The one-letter code says what kind of transaction it was: only P (purchase) and S (sale) are open-market or private trades; awards, option exercises, tax withholding and gifts carry other codes.
Recent Form 4 transactions
The 50 most recent of 114 transactions on file: 2 with code P, 2 with code S and 46 with other codes.
| Date | Insider | Title | Code | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Oct 1, 2026 | Houvras Yariv | CHIEF MEDICAL OFFICER | A Award | 105,000 | Not measured | Not measured |
| Jun 11, 2026 | ROSS ROBERT W. | Director | A Award | 5,000 | Not measured | Not measured |
| Jun 11, 2026 | Curran Daniel J. | Director | A Award | 5,000 | Not measured | Not measured |
| Jun 11, 2026 | Shannon James Samuel | Director | A Award | 5,000 | Not measured | Not measured |
| Jun 11, 2026 | Xu Yuan | Director | A Award | 5,000 | Not measured | Not measured |
| Jun 11, 2026 | Bello Akintunde Olatokumbo | Director | A Award | 5,000 | Not measured | Not measured |
| Jun 11, 2026 | Brennan Aoife | Director | A Award | 5,000 | Not measured | Not measured |
| Jun 11, 2026 | Bonstein Sara | Director | A Award | 5,000 | Not measured | Not measured |
| Apr 15, 2026 | Blanchard Cheryl R | Director | A Award | 10,000 | Not measured | Not measured |
| Mar 26, 2026 | Shannon James Samuel | Director | P Purchase | 5,000 | $8.79 | $43,950 |
| Feb 13, 2026 | GILEAD SCIENCES, INC. | 10% Owner | P Purchase | 3,739,000 | $0.5349 | $1,999,991 |
| Jan 2, 2026 | Frankenfield Christopher James | Chief Financial Officer | S Sale | 502 | $9.00 | $4,522 |
| Jan 2, 2026 | Brennan Kevin M. | SVP, FINANCE AND ACCOUNTING | S Sale | 130 | $9.00 | $1,174 |
| Jan 1, 2026 | Russo Rene | PRESIDENT AND CEO | M Exercise | 3,161 | Not measured | Not measured |
| Jan 1, 2026 | Brennan Kevin M. | SVP, FINANCE AND ACCOUNTING | M Exercise | 5,000 | Not measured | Not measured |
| Jan 1, 2026 | Frankenfield Christopher James | Chief Financial Officer | M Exercise | 19,375 | Not measured | Not measured |
| Jan 1, 2026 | Brennan Kevin M. | SVP, FINANCE AND ACCOUNTING | M Exercise | 357 | Not measured | Not measured |
| Jan 1, 2026 | Luptakova Katarina | CHIEF MEDICAL OFFICER | M Exercise | 16,625 | Not measured | Not measured |
| Jan 1, 2026 | Luptakova Katarina | CHIEF MEDICAL OFFICER | M Exercise | 1,188 | Not measured | Not measured |
| Jan 1, 2026 | Frankenfield Christopher James | Chief Financial Officer | M Exercise | 1,384 | Not measured | Not measured |
| Jan 1, 2026 | Russo Rene | PRESIDENT AND CEO | M Exercise | 44,250 | Not measured | Not measured |
| Dec 31, 2025 | Russo Rene | PRESIDENT AND CEO | A Award | 1,500,258 | Not measured | Not measured |
| Dec 31, 2025 | Brennan Kevin M. | SVP, FINANCE AND ACCOUNTING | A Award | 95,221 | Not measured | Not measured |
| Dec 31, 2025 | Frankenfield Christopher James | Chief Financial Officer | A Award | 668,789 | Not measured | Not measured |
| Dec 31, 2025 | Luptakova Katarina | CHIEF MEDICAL OFFICER | A Award | 451,885 | Not measured | Not measured |
| Nov 26, 2025 | GILEAD SCIENCES, INC. | 10% Owner | X In-the-Money | 13,335,000 | Not measured | Not measured |
| Nov 26, 2025 | GILEAD SCIENCES, INC. | 10% Owner | X In-the-Money | 13,335,000 | $0.7499 | $9,999,917 |
| Nov 21, 2025 | Frankenfield Christopher James | Chief Financial Officer | D Disposition | 37,296 | Not measured | Not measured |
| Nov 21, 2025 | Frankenfield Christopher James | Chief Financial Officer | D Disposition | 45,000 | Not measured | Not measured |
| Nov 21, 2025 | Frankenfield Christopher James | Chief Financial Officer | A Award | 45,000 | Not measured | Not measured |
| Nov 21, 2025 | Frankenfield Christopher James | Chief Financial Officer | A Award | 20,000 | Not measured | Not measured |
| Nov 21, 2025 | Brennan Kevin M. | SVP, FINANCE AND ACCOUNTING | A Award | 131,700 | Not measured | Not measured |
| Nov 21, 2025 | Frankenfield Christopher James | Chief Financial Officer | A Award | 150,000 | Not measured | Not measured |
| Nov 21, 2025 | Frankenfield Christopher James | Chief Financial Officer | D Disposition | 300,000 | Not measured | Not measured |
| Nov 21, 2025 | Frankenfield Christopher James | Chief Financial Officer | A Award | 37,296 | Not measured | Not measured |
| Nov 21, 2025 | Frankenfield Christopher James | Chief Financial Officer | A Award | 925,000 | Not measured | Not measured |
| Nov 21, 2025 | Frankenfield Christopher James | Chief Financial Officer | D Disposition | 117,000 | Not measured | Not measured |
| Nov 21, 2025 | Frankenfield Christopher James | Chief Financial Officer | A Award | 300,000 | Not measured | Not measured |
| Nov 21, 2025 | Brennan Kevin M. | SVP, FINANCE AND ACCOUNTING | D Disposition | 55,000 | Not measured | Not measured |
| Nov 21, 2025 | Frankenfield Christopher James | Chief Financial Officer | A Award | 117,000 | Not measured | Not measured |
| Nov 21, 2025 | Frankenfield Christopher James | Chief Financial Officer | D Disposition | 20,000 | Not measured | Not measured |
| Nov 21, 2025 | Frankenfield Christopher James | Chief Financial Officer | D Disposition | 150,000 | Not measured | Not measured |
| Nov 21, 2025 | Brennan Kevin M. | SVP, FINANCE AND ACCOUNTING | A Award | 55,000 | Not measured | Not measured |
| Nov 21, 2025 | Frankenfield Christopher James | Chief Financial Officer | D Disposition | 23,786 | Not measured | Not measured |
| Nov 21, 2025 | Frankenfield Christopher James | Chief Financial Officer | A Award | 23,786 | Not measured | Not measured |
| Nov 21, 2025 | Brennan Kevin M. | SVP, FINANCE AND ACCOUNTING | D Disposition | 25,000 | Not measured | Not measured |
| Nov 21, 2025 | Brennan Kevin M. | SVP, FINANCE AND ACCOUNTING | A Award | 25,000 | Not measured | Not measured |
| Nov 21, 2025 | Frankenfield Christopher James | Chief Financial Officer | D Disposition | 155,090 | Not measured | Not measured |
| Nov 21, 2025 | Frankenfield Christopher James | Chief Financial Officer | A Award | 155,090 | Not measured | Not measured |
| Nov 21, 2025 | Brennan Kevin M. | SVP, FINANCE AND ACCOUNTING | D Disposition | 20,000 | Not measured | Not measured |
The full Form 4 history is on the XLO company page (Insider Trades card, View all).
Questions about this data
Which insider transactions are open-market trades?
Code P (open market or private purchase) and code S (open market or private sale). Code F is shares withheld to pay tax on vesting stock, A is an award from the company, M and X are option exercises and G is a gift. None of those is the insider choosing to buy or sell in the market.
How quickly are insider trades reported?
A Form 4 is due before the end of the second business day after the trade. The date shown is the transaction date from the form.
Who has to file Form 4?
Officers, directors and beneficial owners of more than 10% of a class of the company’s registered equity, under Section 16 of the Securities Exchange Act.
Look up any code in the Form 4 transaction code reference, or read Form 4 codes explained.